Immunogenicity and safety of Sinovac-CoronaVac booster vaccinations in 12-17- year-olds with clinically significant reactions from Pfizer-BNT162b2 vaccination
Vaccine. 2024 Apr 6:S0264-410X(24)00425-0. doi: 10.1016/j.vaccine.2024.04.011. Online ahead of print.ABSTRACTHeterologous Sinovac-CoronaVac booster(s) in 12-17-year-olds who had a moderate/severe reaction to Pfizer-BNT162b2 mRNA vaccine was found to safe with no serious adverse events reported. In those primed with 1 dose of Pfizer-BNT162b2 vaccine, subsequent boosters with 2 doses of Sinovac-CoronaVac vaccines achieved neutralizing antibody levels which were comparable to those who had received 2 doses of Pfizer-BNT162b2 vaccines followed by 1 dose of Sinovac-CoronaVac vaccination. Adolescents with 1 Pfizer-BNT162b2 follo...
Source: Vaccine - April 7, 2024 Category: Allergy & Immunology Authors: Chia-Yin Chong Kai-Qian Kam Jinyan Zhang Antonio Bertoletti Smrithi Hariharaputran Rehena Sultana Rupini Piragasam Yun-Yan Mah Chee-Wah Tan Linfa Wang Chee-Fu Yung Source Type: research
A phase IIa, randomized, double-blind, safety, immunogenicity and efficacy trial of Plasmodium falciparum vaccine antigens merozoite surface protein 1 and RTS,S formulated with AS02 adjuvant in healthy, malaria-na ïve adults
CONCLUSION: Co-administration of RTS,S and FMP1/AS02 reduced anti-RTS,S antibody, but did not affect tolerability, cellular immunity, or efficacy in a stringent CHMI model. Absence of efficacy or delay of patency in the sporozoite challenge model in the FMP1/AS02 group did not rule out efficacy of FMP1/AS02 in an endemic population. However, a Phase IIb trial of FMP1/AS02 in children in malaria-endemic Kenya did not demonstrate efficacy against natural infection.CLINICALTRIALS: gov identifier: NCT01556945.PMID:38584058 | DOI:10.1016/j.vaccine.2024.03.072 (Source: Vaccine)
Source: Vaccine - April 7, 2024 Category: Allergy & Immunology Authors: J F Cummings M E Polhemus K E Kester C F Ockenhouse R A Gasser P Coyne G Wortmann R K Nielsen K Schaecher C A Holland U Krzych N Tornieporth L A Soisson E Angov D G Heppner RTS,S Vaccine Evaluation Group Source Type: research
Indirect vaccine effectiveness in an outbreak of Alpha B.1.1.7 variant in a California state Prison, May 2021
Vaccine. 2024 Apr 6:S0264-410X(24)00368-2. doi: 10.1016/j.vaccine.2024.03.062. Online ahead of print.ABSTRACTIncarcerated populations experienced high rates of SARS-CoV-2 infection and death during early phases of the COVID-19 pandemic. To evaluate vaccine effectiveness in the carceral context, we investigated the first outbreak of COVID-19 in a California state prison following widespread rollout of vaccines to residents in early 2021. We identified a cohort of 733 state prison residents presumed to be exposed between May 14 and June 22, 2021. 46.9 % (n = 344) were vaccinated, primarily with two doses of mRNA-1273 (n = 33...
Source: Vaccine - April 7, 2024 Category: Allergy & Immunology Authors: Helena Archer Sandra I McCoy David Sears Ada Kwan Martin Kuersten Joe A Lewnard Stefano M Bertozzi Source Type: research
Dendritic cell targeting peptide plus Salmonella FliCd flagellin fused outer membrane protein H (OmpH) demonstrated increased efficacy against infections caused by different Pasteurella multocida serogroups in mouse models
In this study, we modified OmpH with dendritic cell targeting peptide (Depeps) and/or Salmonella FliCd flagellin, and expressed three types of recombinant proteins with the MBP tag (rDepeps-FliC-OmpH-MBP, rDepeps-OmpH-MBP, rFliC-OmpH-MBP). Assessments in mouse models revealed that vaccination with rDepeps-FliC-OmpH-MBP, rDepeps-OmpH-MBP, or rFliC-OmpH-MBP induced significant higher level of antibodies as well as IFN-γ and IL-4 in murine sera than vaccination with rOmpH-MBP (P < 0.5). Vaccination with the three modified proteins also provided increased protection (rDepeps-FliC-OmpH-MBP, 70 %; rDepeps-OmpH-MBP, 50 %; rFl...
Source: Vaccine - April 7, 2024 Category: Allergy & Immunology Authors: Zihao Wang Mixue Wang Fei Wang Yajuan Luo Hanyuan Liu Zhanwei Zhu Xi Huang Lin Hua Huanchun Chen Bin Wu Zhong Peng Source Type: research
Estimating averted illnesses from influenza vaccination for children and pregnant women - El Salvador, Panama, and Peru, 2011-2018
DISCUSSION: Influenza vaccination campaigns in El Salvador, Panama, and Peru conducted between 2011 and 2018 prevented hundreds to thousands of influenza-associated hospitalizations and illnesses in young children and pregnant women. Existing vaccination programs could prevent additional illnesses, using the same number of vaccines, by achieving the highest possible coverage within the first two months of an influenza vaccine campaign.PMID:38584055 | DOI:10.1016/j.vaccine.2024.04.007 (Source: Vaccine)
Source: Vaccine - April 7, 2024 Category: Allergy & Immunology Authors: Anna N Chard Chiedza Machingaidze Sergio Loayza Radhika Gharpure Francisco Nogareda Rosalba Gonz ález Rhina Dom ínguez Yeny O Tinoco Fatimah S Dawood Joseph Daniel Carreon Kathryn E Lafond Jorge Jara Eduardo Azziz-Baumgartner Vanessa Cozza Paula Couto M Source Type: research
Uptake of pneumococcal vaccines in older Australian adults before and after universal public funding of PCV13
CONCLUSIONS: Changes in uptake of PCV13 and PPV23 among those aged 70 + years were consistent with program changes. However, PCV13 uptake was still substantially lower in individuals aged 65-69 years overall and in those with comorbidities.PMID:38584056 | DOI:10.1016/j.vaccine.2024.04.012 (Source: Vaccine)
Source: Vaccine - April 7, 2024 Category: Allergy & Immunology Authors: Fariha Binte Hossain David Muscatello Sanjay Jayasinghe Jitendra Jonnagaddala Bette Liu Source Type: research
Immunogenicity and safety of Sinovac-CoronaVac booster vaccinations in 12-17- year-olds with clinically significant reactions from Pfizer-BNT162b2 vaccination
Vaccine. 2024 Apr 6:S0264-410X(24)00425-0. doi: 10.1016/j.vaccine.2024.04.011. Online ahead of print.ABSTRACTHeterologous Sinovac-CoronaVac booster(s) in 12-17-year-olds who had a moderate/severe reaction to Pfizer-BNT162b2 mRNA vaccine was found to safe with no serious adverse events reported. In those primed with 1 dose of Pfizer-BNT162b2 vaccine, subsequent boosters with 2 doses of Sinovac-CoronaVac vaccines achieved neutralizing antibody levels which were comparable to those who had received 2 doses of Pfizer-BNT162b2 vaccines followed by 1 dose of Sinovac-CoronaVac vaccination. Adolescents with 1 Pfizer-BNT162b2 follo...
Source: Vaccine - April 7, 2024 Category: Allergy & Immunology Authors: Chia-Yin Chong Kai-Qian Kam Jinyan Zhang Antonio Bertoletti Smrithi Hariharaputran Rehena Sultana Rupini Piragasam Yun-Yan Mah Chee-Wah Tan Linfa Wang Chee-Fu Yung Source Type: research
A phase IIa, randomized, double-blind, safety, immunogenicity and efficacy trial of Plasmodium falciparum vaccine antigens merozoite surface protein 1 and RTS,S formulated with AS02 adjuvant in healthy, malaria-na ïve adults
CONCLUSION: Co-administration of RTS,S and FMP1/AS02 reduced anti-RTS,S antibody, but did not affect tolerability, cellular immunity, or efficacy in a stringent CHMI model. Absence of efficacy or delay of patency in the sporozoite challenge model in the FMP1/AS02 group did not rule out efficacy of FMP1/AS02 in an endemic population. However, a Phase IIb trial of FMP1/AS02 in children in malaria-endemic Kenya did not demonstrate efficacy against natural infection.CLINICALTRIALS: gov identifier: NCT01556945.PMID:38584058 | DOI:10.1016/j.vaccine.2024.03.072 (Source: Vaccine)
Source: Vaccine - April 7, 2024 Category: Allergy & Immunology Authors: J F Cummings M E Polhemus K E Kester C F Ockenhouse R A Gasser P Coyne G Wortmann R K Nielsen K Schaecher C A Holland U Krzych N Tornieporth L A Soisson E Angov D G Heppner RTS,S Vaccine Evaluation Group Source Type: research
Indirect vaccine effectiveness in an outbreak of Alpha B.1.1.7 variant in a California state Prison, May 2021
Vaccine. 2024 Apr 6:S0264-410X(24)00368-2. doi: 10.1016/j.vaccine.2024.03.062. Online ahead of print.ABSTRACTIncarcerated populations experienced high rates of SARS-CoV-2 infection and death during early phases of the COVID-19 pandemic. To evaluate vaccine effectiveness in the carceral context, we investigated the first outbreak of COVID-19 in a California state prison following widespread rollout of vaccines to residents in early 2021. We identified a cohort of 733 state prison residents presumed to be exposed between May 14 and June 22, 2021. 46.9 % (n = 344) were vaccinated, primarily with two doses of mRNA-1273 (n = 33...
Source: Vaccine - April 7, 2024 Category: Allergy & Immunology Authors: Helena Archer Sandra I McCoy David Sears Ada Kwan Martin Kuersten Joe A Lewnard Stefano M Bertozzi Source Type: research
Dendritic cell targeting peptide plus Salmonella FliCd flagellin fused outer membrane protein H (OmpH) demonstrated increased efficacy against infections caused by different Pasteurella multocida serogroups in mouse models
In this study, we modified OmpH with dendritic cell targeting peptide (Depeps) and/or Salmonella FliCd flagellin, and expressed three types of recombinant proteins with the MBP tag (rDepeps-FliC-OmpH-MBP, rDepeps-OmpH-MBP, rFliC-OmpH-MBP). Assessments in mouse models revealed that vaccination with rDepeps-FliC-OmpH-MBP, rDepeps-OmpH-MBP, or rFliC-OmpH-MBP induced significant higher level of antibodies as well as IFN-γ and IL-4 in murine sera than vaccination with rOmpH-MBP (P < 0.5). Vaccination with the three modified proteins also provided increased protection (rDepeps-FliC-OmpH-MBP, 70 %; rDepeps-OmpH-MBP, 50 %; rFl...
Source: Vaccine - April 7, 2024 Category: Allergy & Immunology Authors: Zihao Wang Mixue Wang Fei Wang Yajuan Luo Hanyuan Liu Zhanwei Zhu Xi Huang Lin Hua Huanchun Chen Bin Wu Zhong Peng Source Type: research
Estimating averted illnesses from influenza vaccination for children and pregnant women - El Salvador, Panama, and Peru, 2011-2018
DISCUSSION: Influenza vaccination campaigns in El Salvador, Panama, and Peru conducted between 2011 and 2018 prevented hundreds to thousands of influenza-associated hospitalizations and illnesses in young children and pregnant women. Existing vaccination programs could prevent additional illnesses, using the same number of vaccines, by achieving the highest possible coverage within the first two months of an influenza vaccine campaign.PMID:38584055 | DOI:10.1016/j.vaccine.2024.04.007 (Source: Vaccine)
Source: Vaccine - April 7, 2024 Category: Allergy & Immunology Authors: Anna N Chard Chiedza Machingaidze Sergio Loayza Radhika Gharpure Francisco Nogareda Rosalba Gonz ález Rhina Dom ínguez Yeny O Tinoco Fatimah S Dawood Joseph Daniel Carreon Kathryn E Lafond Jorge Jara Eduardo Azziz-Baumgartner Vanessa Cozza Paula Couto M Source Type: research
Uptake of pneumococcal vaccines in older Australian adults before and after universal public funding of PCV13
CONCLUSIONS: Changes in uptake of PCV13 and PPV23 among those aged 70 + years were consistent with program changes. However, PCV13 uptake was still substantially lower in individuals aged 65-69 years overall and in those with comorbidities.PMID:38584056 | DOI:10.1016/j.vaccine.2024.04.012 (Source: Vaccine)
Source: Vaccine - April 7, 2024 Category: Allergy & Immunology Authors: Fariha Binte Hossain David Muscatello Sanjay Jayasinghe Jitendra Jonnagaddala Bette Liu Source Type: research
Immunogenicity and safety of Sinovac-CoronaVac booster vaccinations in 12-17- year-olds with clinically significant reactions from Pfizer-BNT162b2 vaccination
Vaccine. 2024 Apr 6:S0264-410X(24)00425-0. doi: 10.1016/j.vaccine.2024.04.011. Online ahead of print.ABSTRACTHeterologous Sinovac-CoronaVac booster(s) in 12-17-year-olds who had a moderate/severe reaction to Pfizer-BNT162b2 mRNA vaccine was found to safe with no serious adverse events reported. In those primed with 1 dose of Pfizer-BNT162b2 vaccine, subsequent boosters with 2 doses of Sinovac-CoronaVac vaccines achieved neutralizing antibody levels which were comparable to those who had received 2 doses of Pfizer-BNT162b2 vaccines followed by 1 dose of Sinovac-CoronaVac vaccination. Adolescents with 1 Pfizer-BNT162b2 follo...
Source: Vaccine - April 7, 2024 Category: Allergy & Immunology Authors: Chia-Yin Chong Kai-Qian Kam Jinyan Zhang Antonio Bertoletti Smrithi Hariharaputran Rehena Sultana Rupini Piragasam Yun-Yan Mah Chee-Wah Tan Linfa Wang Chee-Fu Yung Source Type: research
A phase IIa, randomized, double-blind, safety, immunogenicity and efficacy trial of Plasmodium falciparum vaccine antigens merozoite surface protein 1 and RTS,S formulated with AS02 adjuvant in healthy, malaria-na ïve adults
CONCLUSION: Co-administration of RTS,S and FMP1/AS02 reduced anti-RTS,S antibody, but did not affect tolerability, cellular immunity, or efficacy in a stringent CHMI model. Absence of efficacy or delay of patency in the sporozoite challenge model in the FMP1/AS02 group did not rule out efficacy of FMP1/AS02 in an endemic population. However, a Phase IIb trial of FMP1/AS02 in children in malaria-endemic Kenya did not demonstrate efficacy against natural infection.CLINICALTRIALS: gov identifier: NCT01556945.PMID:38584058 | DOI:10.1016/j.vaccine.2024.03.072 (Source: Vaccine)
Source: Vaccine - April 7, 2024 Category: Allergy & Immunology Authors: J F Cummings M E Polhemus K E Kester C F Ockenhouse R A Gasser P Coyne G Wortmann R K Nielsen K Schaecher C A Holland U Krzych N Tornieporth L A Soisson E Angov D G Heppner RTS,S Vaccine Evaluation Group Source Type: research
Indirect vaccine effectiveness in an outbreak of Alpha B.1.1.7 variant in a California state Prison, May 2021
Vaccine. 2024 Apr 6:S0264-410X(24)00368-2. doi: 10.1016/j.vaccine.2024.03.062. Online ahead of print.ABSTRACTIncarcerated populations experienced high rates of SARS-CoV-2 infection and death during early phases of the COVID-19 pandemic. To evaluate vaccine effectiveness in the carceral context, we investigated the first outbreak of COVID-19 in a California state prison following widespread rollout of vaccines to residents in early 2021. We identified a cohort of 733 state prison residents presumed to be exposed between May 14 and June 22, 2021. 46.9 % (n = 344) were vaccinated, primarily with two doses of mRNA-1273 (n = 33...
Source: Vaccine - April 7, 2024 Category: Allergy & Immunology Authors: Helena Archer Sandra I McCoy David Sears Ada Kwan Martin Kuersten Joe A Lewnard Stefano M Bertozzi Source Type: research
